Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and raised ...

Notes landmark agreement with U.S. government: Says voluntary agreement provides greater clarity; reduces uncertainty around tariffs and pricing; allows investment in future innovation and growth.

Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...

Pfizer achieved 10% year-over-year Q2 2025 revenue growth to $14.7 billion, driven by Abrysvo RSV vaccine and Seagen-acquired oncology assets. Management expects over $20 billion in risk-adjusted ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...

Pfizer is a large drugmaker with a strong history of working through difficult periods. The pharmaceutical giant's challenges include facing down an impending patent cliff. Pfizer's dividend payout ...

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...